Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 15/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | CASP3 | P42574 | 2/20 | 0.51 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | CASP9 | P55211 | 1/20 | 0.50 |
| ▸ | CASP6 | P55212 | 1/20 | 0.50 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.50 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3563285 | 0.90 | TDP2 (1.00) | TDP2CYP3A4TDP1CASP3MEN1 | |
| SCHEMBL18010848 | 0.84 | TDP2 (1.00) | TDP2PGR | |
| SCHEMBL2616914 | 0.81 | TDP2 (0.73) | TDP2CYP3A4TDP1CASP3CAPN9 | |
| SCHEMBL18010837 | 0.80 | TDP2 (1.00) | TDP2TDP1CASP3MEN1KMT2A | |
| SCHEMBL2993057 | 0.80 | TDP2 (0.67) | TDP2CYP3A4TDP1CASP3CAPN9 | |
| SCHEMBL18010836 | 0.79 | TDP2 (1.00) | TDP2PGR | |
| SCHEMBL8503139 | 0.78 | PTPRC (0.55) | TDP2CYP3A4TDP1CASP3CAPN9 | |
| SCHEMBL2144234 | 0.77 | CYP3A4 (0.54) | TDP2CYP3A4TDP1CASP3CAPN9 | |
| SCHEMBL19954 | 0.77 | PGR (0.71) | TDP2CYP3A4TDP1CASP3CAPN9 | |
| SCHEMBL151957 | 0.75 | CYP3A4 (1.00) | TDP2CYP3A4TDP1CASP3CAPN9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000488-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-19 | — | — | US | disclosed |
| US-20170253591-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-07 | — | — | US | disclosed |
| EP-1640367-B1 | ISOQUINOLINE -1,3,4-TRIONE, THE SYNTHETIC METHOD AND THE USE THEREOF | SHANGHAI INST MATERIA MEDICA (CN) | 2011-02-09 | — | — | EP | disclosed |
| US-7683073-B2 | Isoquinoline-1,3,4-trione compounds, the synthetic method and the use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2010-03-23 | — | — | US | disclosed |
| US-20070105865-A1 | Substituted bicyclic quinazolin-4-ylamine derivatives | NEUROGEN CORPORATION (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070105865-A1 | Substituted bicyclic quinazolin-4-ylamine derivatives | NEUROGEN CORPORATION (US) | 2007-05-10 | — | — | US | disclosed |
| US-20060135557-A1 | Isoquinoline-1,3,4-trione compounds, the synthetic method and the use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES | 2006-06-22 | — | — | US | disclosed |
| EP-1640367-A1 | ISOQUINOLINE -1,3,4-TRIONE, THE SYNTHETIC METHOD AND THE USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2006-03-29 | — | — | EP | disclosed |
| EP-0709370-B1 | Bicyclic compounds useful as platelet aggregation inhibitors | MITSUI CHEMICALS INC (JP) | 1999-01-13 | — | — | EP | disclosed |
| US-5629321-A | FIBRINOGEN ANTAGONIST | MITSUI TOATSU CHEMICALS, INC. (JP) | 1997-05-13 | — | — | US | disclosed |
| EP-0709370-A1 | Bicyclic compounds useful as platelet aggregation inhibitors | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1996-05-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105865-A1 | Substituted bicyclic quinazolin-4-ylamine derivatives | PIGS, HRH4, GPR35 | TDP2 3033/4885CYP3A4 999/4885TDP1 3355/4885 |
| US-20170253591-A1 | HETEROCYCLIC COMPOUND | RORC, RORB, RORA | TDP2 4859/4885CYP3A4 2963/4885TDP1 4856/4885 |
| US-20060135557-A1 | Isoquinoline-1,3,4-trione compounds, the synthetic method and the use thereof | APP, PSEN1, AIFM1 | TDP2 73/4885CYP3A4 980/4885TDP1 34/4885 |
| US-10000488-B2 | Heterocyclic compound | RORC, RORB, RORA | TDP2 4859/4885CYP3A4 2963/4885TDP1 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.